User talk:Z3332250: Difference between revisions

From Embryology
Line 45: Line 45:
alternate treatment of FRDA is through histone deacetylase inhibitor (HDACI) which has shown potential as treatment in reversing heterochromatin of genes<ref name="PMID:16205715"><pubmed>16205715</pubmed></ref>. HDACI has shown sign of increasing levels of fractin to normal range within the nervous system and the heart, positive effects of fractin levels has given signs of decrease in progression of FRDA. Therapeutic use of HDACI led to the normalization of the genetic expression of FRDA patients from the minute levels of fractin. Clearly from mouse models depict therapeutic effect of HDACI, HDACI is able to cross through the blood brain barrier elevating levels of histone acetylation without having toxic effects upon the brain though has shown no affiliation to fractin levels instead affecting GAA repeat<ref name="PMID:18463734"><pubmed>18463734</pubmed></ref>.
alternate treatment of FRDA is through histone deacetylase inhibitor (HDACI) which has shown potential as treatment in reversing heterochromatin of genes<ref name="PMID:16205715"><pubmed>16205715</pubmed></ref>. HDACI has shown sign of increasing levels of fractin to normal range within the nervous system and the heart, positive effects of fractin levels has given signs of decrease in progression of FRDA. Therapeutic use of HDACI led to the normalization of the genetic expression of FRDA patients from the minute levels of fractin. Clearly from mouse models depict therapeutic effect of HDACI, HDACI is able to cross through the blood brain barrier elevating levels of histone acetylation without having toxic effects upon the brain though has shown no affiliation to fractin levels instead affecting GAA repeat<ref name="PMID:18463734"><pubmed>18463734</pubmed></ref>.


Treatment of FRDA through histone deacetylase inhibitor (HDACI) has shown potentials as a treatment in reversing heterochromatin of genes[75]. HDACI has shown sign of increasing levels of fractin up to normal range within the nervous system and the heart, positive effects of fractin levels has produced signs of decrease in progression of FRDA. Therapeutic use of HDACI led to the normalization of the genetic expression of FRDA patients from the minute levels of fractin. Clearly mouse models depict therapeutic effect of HDACI, HDACI is able to cross through the blood brain barrier elevating levels of histone acetylation without having toxic effects upon the brain though has shown no affiliation to fractin levels instead affecting GAA repeat.
Treatment of FRDA through histone deacetylase inhibitor (HDACI) has shown potential as a treatment in reversing heterochromatin of genes<ref name="PMID:16205715"><pubmed>16205715</pubmed></ref>. HDACI has shown signs of increasing levels of fractin restoring to normal range within the nervous system and the heart, restoration of fractin levels was achieved where acetylisation of histones at the GAA repeat in FRDA patients in both the heart and central nervous system<ref name="PMID:16921367"><pubmed>16921367</pubmed></ref>.
 
Positive effects of fractin level restoration is signs of decrease in progression of FRDA. Therapeutic use of HDACI led to the normalization of the genetic expression of FRDA patients. Support of fractin level restoration is clearly identified from the KIKI mouse models depict therapeutic effect of HDACI displaying no signs of pathologyical or abnormal behaviour, while HDACI is able to cross the blood brain barrier and procede with aceytlsation to histones without producing any toxic effects upon the brain where no pathological effects from FRDA where identified<ref name="PMID:18463734"><pubmed>18463734</pubmed></ref>.

Revision as of 22:36, 29 September 2011

Alternate treatment

Iron chelations

Iron chelations potential as treatment for FA is greatly focused. Regarding pathogenesis of FA is due to he mitochondrial accumulation of Iron, causing a usage of cytosolic iron[1].Where most potential chelators are those which specifically target mitochondrial pools of iron[2].There is evidence that due to the fractin deficiency results in FA caused from the depletion of cytosolic iron, it has been suggested therapeutic treatment of iron supplements to replenish cytosolic iron to normal[3].


Articles to read:

"""Carido"""

[4]

Treatment

Currently For the degenerative congenital disorder Friedreichs Ataxia (FRDA) this is no current treatment to reverse, prevent and delay [5]. However there are various potential treatments which have shown signs of improvement from FRDA, antioxidant and Iron chelation are the leading treatments towards FRDA[6][7][8].


friedreich Ataxia (FA) a progressive neurological congenital disorder[9], wtih no treatment identified only possible pharmaceutics which can reduce the progression of FA however not significantly. Whereas significant treatment poties of FA or reduction in progression are the following:

  • Iron-chelation
    • deferoxamine
  • Antioxidants:
    • Idebenone
    • Coenzyme Q10 and Vitamin E

Antioxidants treatment of FA which have shown most promise is Idebenone and Coenzyme Q10 with Vitamin E. Antioxidants have shown degree of reduction on oxidative stress in mitochondria though are still going through clinical trials[5].Conenzyme Q10 an electron carrier with a reduction of oxidative stress effect from the combination of vitamin E, combination of Q10 and vitamin E displayed a positive effect[10]. Where Q10 and vitamin E conveyed the cardiac and skeletal improvement with the betterment of the mitochondrial synthesis[11].

Idebnone operates with a duel function where reversing redox reactions affecting electron balance in the mitochondria while also supporting mitochondria functions preventing damage[7].


genetic treatment

alternate treatment of FRDA is through histone deacetylase inhibitor (HDACI) which has shown potential as treatment in reversing heterochromatin of genes[12]. HDACI has shown sign of increasing levels of fractin to normal range within the nervous system and the heart, positive effects of fractin levels has given signs of decrease in progression of FRDA. Therapeutic use of HDACI led to the normalization of the genetic expression of FRDA patients from the minute levels of fractin. Clearly from mouse models depict therapeutic effect of HDACI, HDACI is able to cross through the blood brain barrier elevating levels of histone acetylation without having toxic effects upon the brain though has shown no affiliation to fractin levels instead affecting GAA repeat[13].

Treatment of FRDA through histone deacetylase inhibitor (HDACI) has shown potential as a treatment in reversing heterochromatin of genes[12]. HDACI has shown signs of increasing levels of fractin restoring to normal range within the nervous system and the heart, restoration of fractin levels was achieved where acetylisation of histones at the GAA repeat in FRDA patients in both the heart and central nervous system[14].

Positive effects of fractin level restoration is signs of decrease in progression of FRDA. Therapeutic use of HDACI led to the normalization of the genetic expression of FRDA patients. Support of fractin level restoration is clearly identified from the KIKI mouse models depict therapeutic effect of HDACI displaying no signs of pathologyical or abnormal behaviour, while HDACI is able to cross the blood brain barrier and procede with aceytlsation to histones without producing any toxic effects upon the brain where no pathological effects from FRDA where identified[13].

  1. ↑ <pubmed>10805340</pubmed>
  2. ↑ <pubmed>20156111</pubmed>
  3. ↑ <pubmed>18424449</pubmed>
  4. ↑ <pubmed>19283344</pubmed>
  5. ↑ 5.0 5.1 <pubmed>19283349</pubmed> Cite error: Invalid <ref> tag; name 'PMID:19283349' defined multiple times with different content
  6. ↑ <pubmed>19283350</pubmed>
  7. ↑ 7.0 7.1 <pubmed>19283347</pubmed>
  8. ↑ <pubmed>17968974</pubmed>
  9. ↑ <pubmed>19283349</pubmed>
  10. ↑ <pubmed>19049556</pubmed>
  11. ↑ <pubmed>15824263</pubmed>
  12. ↑ 12.0 12.1 <pubmed>16205715</pubmed>
  13. ↑ 13.0 13.1 <pubmed>18463734</pubmed>
  14. ↑ <pubmed>16921367</pubmed>
Retrieved from ‘https://embryology.med.unsw.edu.au/embryology/index.php?title=User_talk:Z3332250&oldid=73574’
Powered by MediaWiki